Inovio (INO) Receives Upgrade to Buy: Reasons Behind the Decision
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 14 2025
0mins
Should l Buy INO?
Source: NASDAQ.COM
Inovio Pharmaceuticals Upgrade: Inovio Pharmaceuticals has been upgraded to a Zacks Rank #2 (Buy) due to an upward trend in earnings estimates, indicating a positive outlook for the company's stock price.
Zacks Rating System: The Zacks rating system, which evaluates stocks based on earnings estimate revisions, has a strong track record, with Zacks Rank #1 stocks averaging a +25% annual return since 1988.
Earnings Estimates: Analysts have raised their earnings estimates for Inovio, with a 5% increase in the Zacks Consensus Estimate over the past three months, reflecting an improvement in the company's underlying business.
Market Positioning: The upgrade places Inovio in the top 20% of Zacks-covered stocks, suggesting potential for near-term stock price increases driven by positive earnings revisions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INO
Wall Street analysts forecast INO stock price to rise
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 1.740
Low
3.00
Averages
7.33
High
13.00
Current: 1.740
Low
3.00
Averages
7.33
High
13.00
About INO
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
INOVIO Pharmaceuticals Plans Public Offering of Common Stock
- Public Offering Announcement: INOVIO Pharmaceuticals has announced its intention to offer common stock along with Series A and Series B warrants, with all securities being sold by INOVIO, indicating a proactive approach to capital raising in the market.
- Underwriter Selection: Piper Sandler has been appointed as the sole manager for the public offering, reflecting the company's choice of an experienced financial institution to facilitate the process and ensure successful execution.
- Additional Purchase Option: INOVIO plans to grant the underwriter a 30-day option to purchase up to 15% additional securities, a strategy aimed at flexibly adjusting the financing scale based on market demand, thereby maximizing fundraising efficiency.
- Registration Statement Validity: The registration statement related to this offering was declared effective by the SEC on January 31, 2024, indicating that the company has completed necessary compliance preparations, laying a solid foundation for subsequent fundraising activities.
See More
Inovio Pharmaceuticals Investors Class Action Reminder
- Lawsuit Background: Glancy Prongay Wolke & Rotter LLP reminds investors that April 7, 2026, is the deadline to file a lead plaintiff motion in the class action for those who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, highlighting investor concerns over the company's future prospects.
- Financial Missteps: On August 8, 2024, Inovio released its Q2 2024 financial results, indicating a delay in submitting the Biologics License Application for INO-3107 due to manufacturing issues, which caused the stock price to drop 3.1% to $8.44 per share the following day, directly impacting investor confidence.
- Regulatory Setbacks: On December 29, 2025, Inovio disclosed that the FDA accepted the INO-3107 application on a standard review timeline instead of an accelerated one, leading to a 24.45% drop in stock price to $1.73 per share, further exacerbating investor losses.
- False Statements Allegations: The class action lawsuit alleges that Inovio failed to disclose critical negative information throughout the class period, including manufacturing deficiencies and insufficient data for accelerated approval, resulting in a misunderstanding of the company's prospects and reflecting significant deficiencies in transparency and compliance.
See More
Inovio Pharmaceuticals Securities Class Action Notice
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, that they must apply to be lead plaintiff by April 7, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Inovio made false and misleading statements during the class period, particularly regarding deficiencies in the manufacturing of its CELLECTRA device and overstated prospects for its INO-3107 Biologics License Application, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, demonstrating its strong capabilities and successful track record in this field.
- Investor Guidance: Investors are advised to select qualified counsel with proven success, avoiding firms that act merely as intermediaries, to ensure they receive the best legal representation and support in the class action.
See More
Inovio Pharmaceuticals Class Action Notice Issued
- Class Action Notice: Rosen Law Firm reminds investors who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, to apply as lead plaintiffs by April 7, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that Inovio made false and misleading statements during the class period, failing to disclose manufacturing deficiencies in its CELLECTRA device, which overstated the prospects of its INO-3107 Biologics License Application, thereby impacting investor confidence.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first in 2017 for the number of securities class action settlements, demonstrating its expertise and success in this field.
- Investor Guidance: Investors are advised to select counsel with a proven track record to ensure effective legal support in the class action, avoiding firms that merely act as intermediaries without substantial litigation experience.
See More
Inovio Pharmaceuticals Faces Class Action for Securities Fraud
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Inovio Pharmaceuticals for violations of the Securities Exchange Act, concerning securities purchased between October 10, 2023, and December 26, 2025, with a deadline to contact the firm by April 7, 2026, to participate.
- False Statements Allegation: The complaint alleges that Inovio made false and misleading statements regarding its CELLECTRA device's manufacturing deficiencies and is unlikely to file the INO-3107 BLA by 2H 2024, resulting in investor losses when the truth emerged.
- FDA Review Issues: Inovio failed to provide sufficient evidence for FDA priority review or accelerated approval for its BLA, indicating significant regulatory compliance issues that could impact its future market performance and investor confidence.
- Legal Consequences: Until the class action is certified, investors are not represented by an attorney, and those who choose not to act may remain absent class members, potentially forfeiting their opportunity to recover losses.
See More
Faruqi & Faruqi Investigates Inovio Securities Fraud Claims
- Legal Investigation Initiated: Faruq & Faruq LLP is investigating potential securities fraud claims against Inovio Pharmaceuticals, involving investors who purchased securities between October 10, 2023, and December 26, 2025, indicating significant legal risks that could impact the company's stock price and market trust.
- False Statement Allegations: The complaint alleges that Inovio and its executives violated federal securities laws by failing to disclose deficiencies in the manufacturing of the CELLECTRA device, which could hinder the timely submission of the INO-3107 Biologics License Application (BLA), potentially affecting future regulatory approvals and commercial prospects.
- FDA Review Outcome: On December 29, 2025, the FDA accepted Inovio's INO-3107 BLA but noted that the company did not provide adequate information to justify eligibility for accelerated approval, resulting in a 24.45% drop in stock price, reflecting market concerns about the company's future prospects.
- Investor Rights Protection: Faruq & Faruq LLP reminds investors that April 7 is the deadline to apply to serve as lead plaintiff in the federal securities class action, emphasizing the importance of investor participation in legal proceedings, which could influence future compensation outcomes.
See More
INOVIO Pharmaceuticals Plans Public Offering of Common Stock
- Public Offering Announcement: INOVIO Pharmaceuticals has announced its intention to offer common stock along with Series A and Series B warrants, with all securities being sold by INOVIO, indicating a proactive approach to capital raising in the market.
- Underwriter Selection: Piper Sandler has been appointed as the sole manager for the public offering, reflecting the company's choice of an experienced financial institution to facilitate the process and ensure successful execution.
- Additional Purchase Option: INOVIO plans to grant the underwriter a 30-day option to purchase up to 15% additional securities, a strategy aimed at flexibly adjusting the financing scale based on market demand, thereby maximizing fundraising efficiency.
- Registration Statement Validity: The registration statement related to this offering was declared effective by the SEC on January 31, 2024, indicating that the company has completed necessary compliance preparations, laying a solid foundation for subsequent fundraising activities.
See More
Inovio Pharmaceuticals Investors Class Action Reminder
- Lawsuit Background: Glancy Prongay Wolke & Rotter LLP reminds investors that April 7, 2026, is the deadline to file a lead plaintiff motion in the class action for those who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, highlighting investor concerns over the company's future prospects.
- Financial Missteps: On August 8, 2024, Inovio released its Q2 2024 financial results, indicating a delay in submitting the Biologics License Application for INO-3107 due to manufacturing issues, which caused the stock price to drop 3.1% to $8.44 per share the following day, directly impacting investor confidence.
- Regulatory Setbacks: On December 29, 2025, Inovio disclosed that the FDA accepted the INO-3107 application on a standard review timeline instead of an accelerated one, leading to a 24.45% drop in stock price to $1.73 per share, further exacerbating investor losses.
- False Statements Allegations: The class action lawsuit alleges that Inovio failed to disclose critical negative information throughout the class period, including manufacturing deficiencies and insufficient data for accelerated approval, resulting in a misunderstanding of the company's prospects and reflecting significant deficiencies in transparency and compliance.
See More
Inovio Pharmaceuticals Securities Class Action Notice
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, that they must apply to be lead plaintiff by April 7, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Inovio made false and misleading statements during the class period, particularly regarding deficiencies in the manufacturing of its CELLECTRA device and overstated prospects for its INO-3107 Biologics License Application, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, demonstrating its strong capabilities and successful track record in this field.
- Investor Guidance: Investors are advised to select qualified counsel with proven success, avoiding firms that act merely as intermediaries, to ensure they receive the best legal representation and support in the class action.
See More
Inovio Pharmaceuticals Class Action Notice Issued
- Class Action Notice: Rosen Law Firm reminds investors who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, to apply as lead plaintiffs by April 7, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that Inovio made false and misleading statements during the class period, failing to disclose manufacturing deficiencies in its CELLECTRA device, which overstated the prospects of its INO-3107 Biologics License Application, thereby impacting investor confidence.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first in 2017 for the number of securities class action settlements, demonstrating its expertise and success in this field.
- Investor Guidance: Investors are advised to select counsel with a proven track record to ensure effective legal support in the class action, avoiding firms that merely act as intermediaries without substantial litigation experience.
See More
Inovio Pharmaceuticals Faces Class Action for Securities Fraud
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Inovio Pharmaceuticals for violations of the Securities Exchange Act, concerning securities purchased between October 10, 2023, and December 26, 2025, with a deadline to contact the firm by April 7, 2026, to participate.
- False Statements Allegation: The complaint alleges that Inovio made false and misleading statements regarding its CELLECTRA device's manufacturing deficiencies and is unlikely to file the INO-3107 BLA by 2H 2024, resulting in investor losses when the truth emerged.
- FDA Review Issues: Inovio failed to provide sufficient evidence for FDA priority review or accelerated approval for its BLA, indicating significant regulatory compliance issues that could impact its future market performance and investor confidence.
- Legal Consequences: Until the class action is certified, investors are not represented by an attorney, and those who choose not to act may remain absent class members, potentially forfeiting their opportunity to recover losses.
See More
Faruqi & Faruqi Investigates Inovio Securities Fraud Claims
- Legal Investigation Initiated: Faruq & Faruq LLP is investigating potential securities fraud claims against Inovio Pharmaceuticals, involving investors who purchased securities between October 10, 2023, and December 26, 2025, indicating significant legal risks that could impact the company's stock price and market trust.
- False Statement Allegations: The complaint alleges that Inovio and its executives violated federal securities laws by failing to disclose deficiencies in the manufacturing of the CELLECTRA device, which could hinder the timely submission of the INO-3107 Biologics License Application (BLA), potentially affecting future regulatory approvals and commercial prospects.
- FDA Review Outcome: On December 29, 2025, the FDA accepted Inovio's INO-3107 BLA but noted that the company did not provide adequate information to justify eligibility for accelerated approval, resulting in a 24.45% drop in stock price, reflecting market concerns about the company's future prospects.
- Investor Rights Protection: Faruq & Faruq LLP reminds investors that April 7 is the deadline to apply to serve as lead plaintiff in the federal securities class action, emphasizing the importance of investor participation in legal proceedings, which could influence future compensation outcomes.
See More
